Last reviewed · How we verify
CYT 107
At a glance
| Generic name | CYT 107 |
|---|---|
| Also known as | CYT107, Interleukin-7, rhIL-7 |
| Sponsor | Cytheris SA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immune Reconstitution of Immunosuppressed Sepsis Patients (PHASE2)
- Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy (PHASE2)
- Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer (PHASE1)
- Safety Study of IL-7 in HIV-infected Patients (Inspire) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYT 107 CI brief — competitive landscape report
- CYT 107 updates RSS · CI watch RSS
- Cytheris SA portfolio CI